Fate Therapeutics Inc (FATE) stock
FATENasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q3 FY2026, quarter ended Sep 30, 2026Last filing: 10-Q on Nov 5, 2026Score 6/3016% above fair value
$1.28−0.06 (-4.48%)
Close on Nov 13, 2026Market cap $153.37MP/E –Yield –
Fate Therapeutics total assets
Total assets on the balance sheet at the end of each period.
Fate Therapeutics's total assets was $238.28M at Sep 30, 2026. For fiscal 2025 it was $318.94M, down 27.6% from the year before. Over ten years it grew 16.7% a year on average. The highest annual figure on record is $921.46M in fiscal 2021.
Annual total assets
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | $318.94M | -27.6% |
| FY2024 | Dec 31, 2024 | $440.69M | -12.9% |
| FY2023 | Dec 31, 2023 | $506.22M | -28.3% |
| FY2022 | Dec 31, 2022 | $705.56M | -23.4% |
| FY2021 | Dec 31, 2021 | $921.46M | +48.0% |
| FY2020 | Dec 31, 2020 | $622.46M | +105.9% |
| FY2019 | Dec 31, 2019 | $302.27M | +41.9% |
| FY2018 | Dec 31, 2018 | $213.03M | +102.3% |
| FY2017 | Dec 31, 2017 | $105.29M | +10.8% |
| FY2016 | Dec 31, 2016 | $95.05M | +39.9% |
| FY2015 | Dec 31, 2015 | $67.96M | +32.8% |
| FY2014 | Dec 31, 2014 | $51.18M | -7.9% |
| FY2013 | Dec 31, 2013 | $55.58M | +401.8% |
| FY2012 | Dec 31, 2012 | $11.08M | – |
Quarterly total assets
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | $238.28M | -30.7% |
| Q2 FY2026 | Jun 30, 2026 | $260.10M | -30.0% |
| Q1 FY2026 | Mar 31, 2026 | $284.92M | -28.5% |
| Q4 FY2025 | Dec 31, 2025 | $318.94M | -27.6% |
| Q3 FY2025 | Sep 30, 2025 | $343.67M | -30.6% |
| Q2 FY2025 | Jun 30, 2025 | $371.63M | -29.7% |
| Q1 FY2025 | Mar 31, 2025 | $398.67M | -30.0% |
| Q4 FY2024 | Dec 31, 2024 | $440.69M | -12.9% |
| Q3 FY2024 | Sep 30, 2024 | $494.97M | -9.0% |
| Q2 FY2024 | Jun 30, 2024 | $528.82M | -9.6% |
| Q1 FY2024 | Mar 31, 2024 | $569.89M | -9.6% |
| Q4 FY2023 | Dec 31, 2023 | $506.22M | -28.3% |
| Q3 FY2023 | Sep 30, 2023 | $543.79M | -27.4% |
| Q2 FY2023 | Jun 30, 2023 | $584.76M | -27.5% |
| Q1 FY2023 | Mar 31, 2023 | $630.34M | -26.6% |
| Q4 FY2022 | Dec 31, 2022 | $705.56M | -23.4% |
| Q3 FY2022 | Sep 30, 2022 | $749.35M | -23.9% |
| Q2 FY2022 | Jun 30, 2022 | $807.06M | -20.5% |
| Q1 FY2022 | Mar 31, 2022 | $858.39M | -17.9% |
| Q4 FY2021 | Dec 31, 2021 | $921.46M | +48.0% |
| Q3 FY2021 | Sep 30, 2021 | $984.57M | +57.2% |
| Q2 FY2021 | Jun 30, 2021 | $1.02B | +55.4% |
| Q1 FY2021 | Mar 31, 2021 | $1.05B | +224.9% |
| Q4 FY2020 | Dec 31, 2020 | $622.46M | +105.9% |
| Q3 FY2020 | Sep 30, 2020 | $626.44M | +84.1% |
| Q2 FY2020 | Jun 30, 2020 | $653.59M | +227.0% |
| Q1 FY2020 | Mar 31, 2020 | $321.89M | +45.7% |
| Q4 FY2019 | Dec 31, 2019 | $302.27M | +41.9% |
| Q3 FY2019 | Sep 30, 2019 | $340.21M | +54.7% |
| Q2 FY2019 | Jun 30, 2019 | $199.88M | +140.4% |
| Q1 FY2019 | Mar 31, 2019 | $220.87M | +136.4% |
| Q4 FY2018 | Dec 31, 2018 | $213.03M | +102.3% |
| Q3 FY2018 | Sep 30, 2018 | $219.95M | +202.7% |
| Q2 FY2018 | Jun 30, 2018 | $83.16M | +12.4% |
| Q1 FY2018 | Mar 31, 2018 | $93.42M | +9.5% |
| Q4 FY2017 | Dec 31, 2017 | $105.29M | +10.8% |
| Q3 FY2017 | Sep 30, 2017 | $72.68M | – |
| Q2 FY2017 | Jun 30, 2017 | $73.95M | – |
| Q1 FY2017 | Mar 31, 2017 | $85.33M | – |
| Q4 FY2016 | Dec 31, 2016 | $95.05M | – |
See a number that looks wrong?